+

PE20090329A1 - Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos - Google Patents

Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Info

Publication number
PE20090329A1
PE20090329A1 PE2008000921A PE2008000921A PE20090329A1 PE 20090329 A1 PE20090329 A1 PE 20090329A1 PE 2008000921 A PE2008000921 A PE 2008000921A PE 2008000921 A PE2008000921 A PE 2008000921A PE 20090329 A1 PE20090329 A1 PE 20090329A1
Authority
PE
Peru
Prior art keywords
cdr
containing seq
globulomer
antibodies against
humanized antibodies
Prior art date
Application number
PE2008000921A
Other languages
English (en)
Inventor
Stefan Barghorn
Heinz Hillen
Patrick Keller
Andreas R Striebinger
Boris Labkovsky
Paul R Hinton
Veronica M Juan
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090329(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of PE20090329A1 publication Critical patent/PE20090329A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE UNION TAL COMO UNA MOLECULA DE INMUNOGLOBULINA, UN ANTICUERPO MONOCLONAL, UN ANTICUERPO HUMANIZADO, UN Fab, ENTRE OTROS, QUE COMPRENDE UN DOMINIO DE UNION A ANTIGENO QUE SE UNE AL GLOBULOMERO BETA AMILOIDE(20-42) QUE COMPRENDE UNA CDR CUYA SECUENCIA DE AMINOACIDOS CONSISTE EN: A) CDR-VH1 QUE CONTIENE LA SEC ID Nº 5; B) CDR-VH2 QUE CONTIENE LA SEC ID Nº 6; C) CDR-VH3 QUE CONTIENE LA SEC ID Nº 7; D) CDR-VL1 QUE CONTIENE LA SEC ID Nº 8; E) CDR-VL2 QUE CONTIENE LA SEC ID Nº 9; CDR-VL3 QUE CONTIENE LA SEC ID Nº 10. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHA PROTEINA DE UNION O UN ANTICUERPO CONJUGADO EN FORMA DE CRISTAL, SIENDO UTIL EN EL TRATAMIENTO Y DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER
PE2008000921A 2007-05-30 2008-05-29 Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos PE20090329A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94093207P 2007-05-30 2007-05-30
US99035907P 2007-11-27 2007-11-27

Publications (1)

Publication Number Publication Date
PE20090329A1 true PE20090329A1 (es) 2009-03-27

Family

ID=39791050

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000921A PE20090329A1 (es) 2007-05-30 2008-05-29 Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Country Status (22)

Country Link
US (1) US20090175847A1 (es)
EP (1) EP2150563A1 (es)
JP (1) JP2010530740A (es)
KR (1) KR20100032398A (es)
CN (1) CN101827862A (es)
AR (1) AR066794A1 (es)
AU (1) AU2008260062A1 (es)
BR (1) BRPI0812005A2 (es)
CA (1) CA2687414A1 (es)
CL (1) CL2008001580A1 (es)
CO (1) CO6251291A2 (es)
CR (1) CR11179A (es)
DO (1) DOP2009000269A (es)
EC (1) ECSP099833A (es)
IL (1) IL202243A0 (es)
MX (1) MX2009012950A (es)
PA (1) PA8782201A1 (es)
PE (1) PE20090329A1 (es)
RU (1) RU2009149370A (es)
TW (1) TW200914465A (es)
UY (1) UY31114A1 (es)
WO (1) WO2008150949A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7497827B2 (en) 2004-07-13 2009-03-03 Dexcom, Inc. Transcutaneous analyte sensor
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US7999082B2 (en) * 2004-02-10 2011-08-16 National Jewish Medical And Research Center Anti-factor B antibodies
US20060270922A1 (en) 2004-07-13 2006-11-30 Brauker James H Analyte sensor
DK3540062T3 (da) * 2004-11-16 2021-06-28 Humanigen Inc Immunoglobulin-variabel region kassetteudskiftning
JP5707024B2 (ja) * 2005-05-26 2015-04-22 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
KR101591223B1 (ko) * 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
CA2657681C (en) * 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7964705B2 (en) 2007-03-14 2011-06-21 Taligen Therapeutics, Inc. Humaneered anti-factor B antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
AU2009245354C1 (en) 2008-05-09 2016-05-19 AbbVie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013202020B2 (en) * 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
KR20130010114A (ko) 2010-03-03 2013-01-25 베링거 인겔하임 인터내셔날 게엠베하 바이파라토픽 ａ-베타 결합 폴리펩타이드
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
EP2558494B1 (en) * 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
CN102516360B (zh) * 2011-12-08 2013-11-06 清华大学 一种抑制β分泌酶酶切作用的多肽及其应用
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
PT2906597T (pt) 2012-10-15 2020-06-18 Medimmune Ltd Anticorpos para amilóide beta
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
CN115175932A (zh) * 2019-07-16 2022-10-11 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途
CN117491650B (zh) * 2023-11-01 2024-09-20 首都医科大学宣武医院 一种外周血Hb-Aβ复合物定量检测试剂盒、检测方法及应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529938A (en) * 1983-02-14 1985-07-16 Shell Oil Company High frequency induction method for locating the interface between formations having the same resistivity
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US6492107B1 (en) * 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) * 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) * 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU642932B2 (en) * 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
JP3068180B2 (ja) * 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) * 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de) * 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
US5290540A (en) * 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
JP4157160B2 (ja) * 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5565352A (en) * 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU705616B2 (en) * 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1997032572A2 (en) * 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DE60114830T2 (de) * 2000-06-28 2006-08-03 Glycofi, Inc. Verfahren zur herstellung modifizierter glycoproteine
ES2405551T3 (es) * 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MX2007013825A (es) * 2005-05-05 2008-01-18 Merck & Co Inc Composiciones de un conjugado peptidico y metodos para la prevencion y tratamiento de la enfermedad de alzheimer.

Also Published As

Publication number Publication date
CO6251291A2 (es) 2011-02-21
CA2687414A1 (en) 2008-12-11
AU2008260062A1 (en) 2008-12-11
WO2008150949A1 (en) 2008-12-11
KR20100032398A (ko) 2010-03-25
EP2150563A1 (en) 2010-02-10
BRPI0812005A2 (pt) 2019-09-24
TW200914465A (en) 2009-04-01
CN101827862A (zh) 2010-09-08
UY31114A1 (es) 2009-01-05
CR11179A (es) 2010-05-27
IL202243A0 (en) 2010-06-16
US20090175847A1 (en) 2009-07-09
DOP2009000269A (es) 2009-12-15
PA8782201A1 (es) 2009-02-09
CL2008001580A1 (es) 2008-12-05
RU2009149370A (ru) 2011-07-10
AR066794A1 (es) 2009-09-09
ECSP099833A (es) 2010-01-29
JP2010530740A (ja) 2010-09-16
MX2009012950A (es) 2010-03-26

Similar Documents

Publication Publication Date Title
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
PE20120415A1 (es) Anticuerpos anti-igf
PE20211217A1 (es) Anticuerpos estabilizadores de trem2
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20090368A1 (es) Anticuerpos anti-igf
RS54424B1 (en) HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
PE20110561A1 (es) Anticuerpos contra il-6
EP2352523A4 (en) ANTI-CD19 ENHANCED ANTIBODIES
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
EA201792376A3 (ru) Молекулы анти-gcc антитела и соответствующие композиции и способы
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
RS54271B1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
PE20131209A1 (es) Anticuerpos anti-fap
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
UY30524A1 (es) Anticuerpos dirigidos a avb(beta)6 y sus usos
RS52860B (en) ANTI-ILT7 ANTITELO
PE20071055A1 (es) Anticuerpos anti mn

Legal Events

Date Code Title Description
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载